Results 41 to 50 of about 11,227 (157)

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Journal of Fungi, 2020
Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth, Lajos Forgács, Tamás Kardos, Renátó Kovács, Jeffrey B. Locke, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, Awid Adnan, László Majoros   +9 more
doaj   +1 more source

Genomic Diversity across Candida auris Clinical Isolates Shapes Rapid Development of Antifungal Resistance In Vitro and In Vivo

mBio, 2022
Antifungal drug resistance and tolerance pose a serious threat to global public health. In the human fungal pathogen, Candida auris, resistance to triazole, polyene, and echinocandin antifungals is rising, resulting in multidrug resistant isolates. Here,
Laura S. Burrack, Robert T. Todd, Natthapon Soisangwan, Nathan P. Wiederhold, Anna Selmecki   +4 more
doaj   +1 more source

Comparison of echinocandin antifungals

Therapeutics and Clinical Risk Management, 2007
The incidence of invasive fungal infections, especially those due to Aspergillus spp. and Candida spp., continues to increase. Despite advances in medical practice, the associated mortality from these infections continues to be substantial. The echinocandin antifungals provide clinicians with another treatment option for serious fungal infections ...
Gregory, Eschenauer, Daryl D, Depestel, Peggy L, Carver   +2 more
openaire   +3 more sources

Synergistic activity of caspofungin and posaconazole against Candida (Candidozyma) auris biofilms based on phenotypic, transcriptomic, and in vivo insights

Microbiology Spectrum
Candida (Candidozyma) auris is an emerging multidrug-resistant fungal pathogen capable of establishing persistent skin colonization, contaminating the environment, and causing nosocomial outbreaks associated with high mortality rates.
Fruzsina Kovács, Andrea Harmath, Dávid Balázsi, Lajos Forgács, Ágota Ragyák, Noémi Balla, Zoltán Tóth, Aliz Bozó, Andrew M. Borman, László Majoros, Renátó Kovács, Ágnes Jakab   +11 more
doaj   +1 more source

FDA-Approved Antibacterials and Echinocandins

Antibiotics
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA).
Othman Al Musaimi
doaj   +1 more source

Application of an aculeacin A acylase from Actinoplanes utahensis SW1311 in syntheses of echinocandins

浙江大学学报. 农业与生命科学版, 2017
Echinocandins are the first class of antifungals to target fungal cell wall. Two antifungals, including micafungin and anidulafungin, have been widely used in clinic.
FENG Guodong, XU Yongfeng, CHEN Jianfeng, ZHAO Wanzhong, WANG Xin, ZHANG Xiaosheng, JIANG Hui   +6 more
doaj   +1 more source

Novel Cell Wall Antifungals Reveal a Special Synergistic Activity in pbr1 Mutants Resistant to the Glucan Synthesis Antifungals Papulacandins and Echinocandins

Frontiers in Microbiology, 2019
A series of 4-(arylmethylene)-3-isochromanones have been prepared with base-catalyzed Knoevenagel condensation starting from 3-isochromanone and aromatic aldehydes.
Rodrigo Berzaghi, Attila Agócs, María A. Curto, Gergely Gulyás-Fekete, Béla Kocsis, Juan C. Ribas, Tamás Lóránd   +6 more
doaj   +1 more source

Treatment of invasive candidiasis with echinocandins [PDF]

Mycoses, 2009
SummaryBlood stream infections by Candida spp. represent the majority of invasive fungal infections in intensive care patients. The high crude mortality of invasive candidiasis remained essentially unchanged during the last two decades despite new treatment options that became available.
Andreas, Glöckner, Angela, Steinbach, Jörg Janne, Vehreschild, Oliver A, Cornely   +3 more
openaire   +2 more sources

Treatment of Invasive Candidiasis: A Narrative Review

Journal of Fungi, 2018
Invasive candidiasis occurs frequently in hospitalized patients, and is associated with high mortality rates due to delays in recognition and initiation of appropriate antifungals.
Ronen Ben-Ami
doaj   +1 more source

Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies

Journal of Fungi, 2020
Background. Candida tropicalis is a virulent fungal pathogen for which echinocandins are the primary therapy. Emergence of resistance to echinocandins of C. tropicalis carries potentially ominous therapeutic implications. Methods.
Maroun M. Sfeir, Cristina Jiménez-Ortigosa, Maria N. Gamaletsou, Audrey N. Schuetz, Rosemary Soave, Koen Van Besien, Catherine B. Small, David S. Perlin, Thomas J. Walsh   +8 more
doaj   +1 more source